OmniAb signs global ion channel collaboration deal with Eli Lilly, eyes up to $370 million in milestones

PUBT · 2d ago
OmniAb signs global ion channel collaboration deal with Eli Lilly, eyes up to $370 million in milestones
  • OmniAb entered a global collaboration and license agreement with Eli Lilly for a new ion channel discovery program.
  • Deal includes an upfront payment. OmniAb can earn up to USD 370 million in research, development, commercial milestones.
  • Agreement also provides tiered royalties on global net sales.
  • Therapeutic target, modality were not disclosed.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OmniAb Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202608170601BIZWIRE_USPR_____20260812_BW350809) on August 17, 2026, and is solely responsible for the information contained therein.